Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB.
Departments of *Pediatric Oncology †Orthopaedics and Traumatology ‡Radiology §Radiation Oncology ∥Pathology, Kocaeli University, Umuttepe, 41380 Kocaeli/Turkey.
Ugur
U
Demirsoy
Meriban
M
Karadogan
Özgür
Ö
Selek
Yonca
Y
Anik
Görkem
G
Aksu
Bahar
B
Müezzinoglu
Funda
F
Corapcioglu
D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069448:Denosumab; D005260:Female; D018212:Giant Cell Tumor of Bone / Q000188:drug therapy*; D006801:Humans; D009362:Neoplasm Metastasis; D016879:Salvage Therapy / Q000379:methods
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069448:Denosumab